摘要
有研究证明氧化应激在炎症和异常免疫应答的发展和修复过程中起着关键的作用。氧化应激的生物标记物可能定义了病理学条件下的氧化损伤的比例,同时也预见和监测了那些被设计用来控制病理学的治疗策略的潜在有效性。可以被用作生物标记物的新化合物已经被鉴定出,其中晚期氧化蛋白产物(AOPPs)主要由髓过氧化酶的激活产生的氯代氧化物形成的。本文旨在回顾关于晚期氧化蛋白产物在与炎症阶段和免疫失调临床疾病和慢性发展进程中作为氧化损伤的生物标记物的潜在价值的证据。这些病理学包括代谢综合征、肥胖、免疫介导的炎症疾病、神经衰弱疾病以及肿瘤。由于对晚期氧化蛋白产物积累所报道的病理学特征异质性,晚期氧化蛋白产物明显不仅仅是激活嗜中性粒细胞的一个标记物,但同时晚期氧化产物不总是疾病的决定因素。本综述所报道的数据证实了一个观点,那就是晚期氧化蛋白产物可成功用于体外炎症和免疫介导疾病的确诊,但同时证据显示可能是由于晚期氧化蛋白产物形成的方式与他们诱导的功能一致,晚期氧化蛋白产物价值还不能完全清楚地反映它们与病理学以及特殊疾病发展史的联系。
关键词: 晚期氧化蛋白产物;生物标记物;临床研究;氧化应激;髓过氧化物酶;炎症;免疫失调
Current Medicinal Chemistry
Title:Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Volume: 23 Issue: 34
Author(s): Mariateresa Cristani, Antonio Speciale, Antonella Saija, Sebastiano Gangemi, Paola Lucia Minciullo, Francesco Cimino
Affiliation:
关键词: 晚期氧化蛋白产物;生物标记物;临床研究;氧化应激;髓过氧化物酶;炎症;免疫失调
摘要: Evidence came out showing that oxidative stress has a pivotal role in development and maintenance of inflammation and aberrant immune responses. Biomarkers of oxidative stress may define the proportion of oxidative damage underlying pathological conditions, and also foresee and monitor the possible efficacy of therapeutic strategies designed to control these pathologies. New compounds, which can be used as biomarkers, have been identified, and among them advanced oxidation protein products (AOPPs), formed mainly by chlorinated oxidants resulting from activity of myeloperoxidase. Our paper is aimed to review clinical evidences concerning the valuable potential of AOPPs as biomarkers of oxidative injury in development and progression of diseases and chronic conditions related to inflammatory status and immune dysregulation. These pathologies include metabolic syndrome, obesity, immune-mediated inflammatory diseases, neurodegenerative diseases, and cancer. Due to the heterogeneity of pathologies reported to be characterized by AOPP accumulation, it is evident that AOPPs are not merely a marker of neutrophil activation, but at the same time AOPPs cannot always be disease determinants. The data reported in this review corroborate the opinion that AOPPs can be successfully used to in vitro confirm the diagnosis of inflammatory and immune-mediated diseases, but at the same time evidence is that, very likely due to the way through which AOPPs are formed as well as the effect they can contribute to induce, AOPP values cannot be clearly reflective of their involvement in the pathogenesis and in the evolution of a specific disease.
Export Options
About this article
Cite this article as:
Mariateresa Cristani, Antonio Speciale, Antonella Saija, Sebastiano Gangemi, Paola Lucia Minciullo, Francesco Cimino , Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation, Current Medicinal Chemistry 2016; 23 (34) . https://dx.doi.org/10.2174/0929867323666160902154748
DOI https://dx.doi.org/10.2174/0929867323666160902154748 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brown Recluse Spider Venom: Proteomic Analysis and Proposal of a Putative Mechanism of Action
Protein & Peptide Letters Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study
Current Drug Targets Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets The Treatment of Chronic Hepatitis C not Responding to Interferon
Current Pharmaceutical Design The Biology and Therapeutic Potential of the DDAH/ADMA Pathway
Current Pharmaceutical Design Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews The Influence of Different Disease States on Rituximab Pharmacokinetics
Current Drug Metabolism Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation
Current Pharmaceutical Design Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Giant Cell Arteritis (GCA): Pathogenesis, Clinical Aspects and Treatment Approaches
Current Rheumatology Reviews Editorial [Hot Topic: Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets Executive (Guest Editor: Armen Yuri Gasparyan)]
Current Pharmaceutical Design Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design An Update on the Cardiovascular Effects of Quercetin, a Plant Flavonoid
Current Nutrition & Food Science Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Editorial: Cocaine and Acute Basilar Artery Occlusion: What we Know to Date?
Current Vascular Pharmacology